<a href="https://www.fiercebiotech.com/medtech/thermo-fisher-sees-higher-q1-earnings-amid-strong-biopharma-demand" hreflang="en">Thermo Fisher sees higher Q1 earnings amid strong biopharma demand</a>
Thermo Fisher Scientific reported a strong first quarter in 2026, with revenues rising 6% to $11.01 billion, driven by high demand from biopharma customers and the recent acquisition of Clario, which contributed additional revenue. The company also increased its revenue and earnings guidance for the year, citing growth opportunities in artificial intelligence and ongoing market resilience despite inflationary pressures.
Thermo Fisher's strategic acquisition of Clario and its collaboration with Nvidia to enhance AI-driven laboratory infrastructure highlight significant investment opportunities in AI integration and data capabilities in biopharma. As AI is positioned to improve drug development ROI, investing in companies leveraging AI for precision medicine and drug discovery could yield substantial returns, aligning with the growing interest in the biotech sector.